UniProtKB/Swiss-Prot P21709: Variant p.Met900Val

Ephrin type-A receptor 1
Gene: EPHA1
Feedback?

Variant information Variant position:

900 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Methionine (M) to Valine (V) at position 900 (M900V, p.Met900Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs6967117 [ dbSNP | Ensembl ]

Sequence information Variant position:

900 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

976 The length of the canonical sequence.
Location on the sequence:

LEQLLANPHSLRTIANFDPR M TLRLPSLSGSDGIPYRTVSE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LEQLLANPHSLRTIANFDPRMTLRLPSLSGSDGIPYRTVSE

Mouse                         LEQLLTDPHSLRTIANFDPRVTLRLPSLSGSDGIPYRSVSE

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	26 – 976	Ephrin type-A receptor 1
Topological domain	569 – 976	Cytoplasmic
Modified residue	906 – 906	Phosphoserine
Modified residue	910 – 910	Phosphoserine
Alternative sequence	475 – 976	Missing. In isoform 3.
Alternative sequence	491 – 976	Missing. In isoform 2.

Literature citations
A novel putative tyrosine kinase receptor encoded by the eph gene.
Hirai H.; Maru Y.; Hagiwara K.; Nishida J.; Takaku F.;
Science 238:1717-1720(1987)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS ALA-160 AND VAL-900; Genomic structure of the EPHA1 receptor tyrosine kinase gene.
Owshalimpur D.; Kelley M.J.;
Mol. Cell. Probes 13:169-173(1999)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS ALA-160 AND VAL-900; Human chromosome 7: DNA sequence and biology.
Scherer S.W.; Cheung J.; MacDonald J.R.; Osborne L.R.; Nakabayashi K.; Herbrick J.-A.; Carson A.R.; Parker-Katiraee L.; Skaug J.; Khaja R.; Zhang J.; Hudek A.K.; Li M.; Haddad M.; Duggan G.E.; Fernandez B.A.; Kanematsu E.; Gentles S.; Christopoulos C.C.; Choufani S.; Kwasnicka D.; Zheng X.H.; Lai Z.; Nusskern D.R.; Zhang Q.; Gu Z.; Lu F.; Zeesman S.; Nowaczyk M.J.; Teshima I.; Chitayat D.; Shuman C.; Weksberg R.; Zackai E.H.; Grebe T.A.; Cox S.R.; Kirkpatrick S.J.; Rahman N.; Friedman J.M.; Heng H.H.Q.; Pelicci P.G.; Lo-Coco F.; Belloni E.; Shaffer L.G.; Pober B.; Morton C.C.; Gusella J.F.; Bruns G.A.P.; Korf B.R.; Quade B.J.; Ligon A.H.; Ferguson H.; Higgins A.W.; Leach N.T.; Herrick S.R.; Lemyre E.; Farra C.G.; Kim H.-G.; Summers A.M.; Gripp K.W.; Roberts W.; Szatmari P.; Winsor E.J.T.; Grzeschik K.-H.; Teebi A.; Minassian B.A.; Kere J.; Armengol L.; Pujana M.A.; Estivill X.; Wilson M.D.; Koop B.F.; Tosi S.; Moore G.E.; Boright A.P.; Zlotorynski E.; Kerem B.; Kroisel P.M.; Petek E.; Oscier D.G.; Mould S.J.; Doehner H.; Doehner K.; Rommens J.M.; Vincent J.B.; Venter J.C.; Li P.W.; Mural R.J.; Adams M.D.; Tsui L.-C.;
Science 300:767-772(2003)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANTS ALA-160 AND VAL-900; Submission
Mural R.J.; Istrail S.; Sutton G.G.; Florea L.; Halpern A.L.; Mobarry C.M.; Lippert R.; Walenz B.; Shatkay H.; Dew I.; Miller J.R.; Flanigan M.J.; Edwards N.J.; Bolanos R.; Fasulo D.; Halldorsson B.V.; Hannenhalli S.; Turner R.; Yooseph S.; Lu F.; Nusskern D.R.; Shue B.C.; Zheng X.H.; Zhong F.; Delcher A.L.; Huson D.H.; Kravitz S.A.; Mouchard L.; Reinert K.; Remington K.A.; Clark A.G.; Waterman M.S.; Eichler E.E.; Adams M.D.; Hunkapiller M.W.; Myers E.W.; Venter J.C.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANTS ALA-160 AND VAL-900; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANTS ALA-160 AND VAL-900; An EGFR/eph chimeric receptor possesses ligand stimulated tyrosine kinase activity and promotes cell growth.
Tuzi N.L.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 286-976 (ISOFORM 1); VARIANT VAL-900; Patterns of somatic mutation in human cancer genomes.
Greenman C.; Stephens P.; Smith R.; Dalgliesh G.L.; Hunter C.; Bignell G.; Davies H.; Teague J.; Butler A.; Stevens C.; Edkins S.; O'Meara S.; Vastrik I.; Schmidt E.E.; Avis T.; Barthorpe S.; Bhamra G.; Buck G.; Choudhury B.; Clements J.; Cole J.; Dicks E.; Forbes S.; Gray K.; Halliday K.; Harrison R.; Hills K.; Hinton J.; Jenkinson A.; Jones D.; Menzies A.; Mironenko T.; Perry J.; Raine K.; Richardson D.; Shepherd R.; Small A.; Tofts C.; Varian J.; Webb T.; West S.; Widaa S.; Yates A.; Cahill D.P.; Louis D.N.; Goldstraw P.; Nicholson A.G.; Brasseur F.; Looijenga L.; Weber B.L.; Chiew Y.-E.; DeFazio A.; Greaves M.F.; Green A.R.; Campbell P.; Birney E.; Easton D.F.; Chenevix-Trench G.; Tan M.-H.; Khoo S.K.; Teh B.T.; Yuen S.T.; Leung S.Y.; Wooster R.; Futreal P.A.; Stratton M.R.;
Nature 446:153-158(2007)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] ALA-160; CYS-351; GLN-492; GLN-575; THR-585; LEU-697; LYS-703; ARG-807 AND VAL-900; Large-scale proteomics analysis of the human kinome.
Oppermann F.S.; Gnad F.; Olsen J.V.; Hornberger R.; Greff Z.; Keri G.; Mann M.; Daub H.;
Mol. Cell. Proteomics 8:1751-1764(2009)
Cited for: VARIANT [LARGE SCALE ANALYSIS] VAL-900; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS];

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.